Amphotericin B-associated hyperbilirubinemia: case report and review of the literature.
A 53-year-old woman with an intraabdominal infection secondary to Candida albicans experienced hyperbilirubinemia after receiving amphotericin B in two different formulations--amphotericin B deoxycholate and amphotericin B lipid complex. Only a few case reports of amphotericin B-induced hyperbilirubinemia have been documented in the literature, each with different patterns of corresponding abnormalities in liver function tests. The unpredictable nature of this adverse effect warrants monitoring of bilirubin levels and liver function at baseline and potentially during therapy with amphotericin B, regardless of formulation, dosage, or duration of therapy.
Olin
Jacqueline L
JL
Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy-Rutgers, State University of New Jersey, Piscataway 08854-8020, USA. jlolin@rci.rutgers.edu
Spooner
Linda M
LM
D000666:Amphotericin B / Q000009:adverse effects* / Q000627:therapeutic use; D000935:Antifungal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002177:Candidiasis / Q000150:complications / Q000188:drug therapy*; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications; D003840:Deoxycholic Acid / Q000009:adverse effects* / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006932:Hyperbilirubinemia / Q000097:blood / Q000139:chemically induced*; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008875:Middle Aged; D010713:Phosphatidylcholines / Q000009:adverse effects* / Q000627:therapeutic use; D010715:Phosphatidylglycerols / Q000009:adverse effects* / Q000627:therapeutic use
D000935:Antifungal Agents; D004338:Drug Combinations; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D003840:Deoxycholic Acid; D000666:Amphotericin B; C059765:amphotericin B, deoxycholate drug combination